• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

    2014-03-29 06:39:45TeresaKimRodabeAmariaChristineSpencerAlexandreReubenZacharyCooperJenniferWargo
    Cancer Biology & Medicine 2014年4期

    Teresa Kim*, Rodabe N. Amaria*, Christine Spencer, Alexandre Reuben, Zachary A. Cooper,, Jennifer A. Wargo,

    1Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA;

    2Harvard Medical School, Boston, MA 02115, USA;

    3Department of Melanoma Medical Oncology,

    4Department of Genomic Medicine,

    5Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

    Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

    Teresa Kim1,2*, Rodabe N. Amaria3*, Christine Spencer4, Alexandre Reuben5, Zachary A. Cooper4,5, Jennifer A. Wargo4,5

    1Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA;

    2Harvard Medical School, Boston, MA 02115, USA;

    3Department of Melanoma Medical Oncology,

    4Department of Genomic Medicine,

    5Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

    Melanoma is the deadliest form of skin cancer and has an incidence that is rising faster than any other solid tumor. Metastatic melanoma treatment has considerably progressed in the past fi ve years with the introduction of targeted therapy (BF and MEK inhibitors) and immune checkpoint blockade (anti-CTLA4, anti-PD-1, and anti-PD-L1). However, each treatment modality has limitations. Treatment with targeted therapy has been associated with a high response rate, but with short-term responses. Conversely, treatment with immune checkpoint blockade has a lower response rate, but with longterm responses. Targeted therapy a ff ects antitumor immunity, and synergy may exist when targeted therapy is combined with immunotherapy.is article presents a brief review of the rationale and evidence for the potential synergy between targeted therapy and immune checkpoint blockade. Challenges and directions for future studies are also proposed.

    Melanoma; checkpoint blockade; BF inhibition; immunotherapy

    Introduction

    Epidemiology of melanoma

    Skin cancer is among the most common cancer types globally1. Melanoma is the deadliest skin cancer2. Its burden on public health continues to rise, with its incidence increasing faster than any other cancer in recent years1,2. Early stage melanoma is treatable with surgery, but the late stage of this disease is oen fatal3. This review discusses the treatment options for patients with advanced melanoma and the rationale for combining targeted therapy and immune checkpoint inhibitors to treat these patients.

    Treatments for advanced melanoma

    Chemotherapy

    Treatment options for advanced melanoma were limited in the past decade, and prognosis was universally poor. Cytotoxic chemotherapy was the main treatment strategy but was marginally e ff ective only in the treatment of locally advanced or metastatic disease. Dacarbazine [5(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide] was the primary agent used, and this drug remains the only FDA-approved chemotherapy for metastatic melanoma. However, therapy is characterized with low overall response rates (approximately 10%-15%), and the drug o ff ers no survival bene fi t4,5.

    In addition to dacarbazine treatment, biochemotherapy regimens and combined chem otherapeutic agents (e.g., dacarbazine or temozolomide with vinblastine and cisplatin) with cytokine-based therapy [e.g., interleukin-2 (IL-2) and interferon-alpha] had been administered to improve response rates by inducing immunogenic cell death. Two large metaanalyses that evaluated the standard chemotherapy versusbiochemotherapy in 18 randomized controlled trials (RCTs) involving more than 2,600 patients with metastatic melanoma show that biochemotherapy regimens can improve overall response rates, but with greater systemic toxicity and without a statistically signi fi cant survival bene fi t6,7.

    Immunotherapy

    Another modality in melanoma treatment involves the use of immunotherapy. The first immune-based therapy with demonstrated clinical benefit in melanoma patients was IL-2, an immune stimulating cytokine integral to T cell activation and proliferation. Atkins et al.8examined 270 patients with metastatic melanoma treated with high dose IL-2, and 16% of patients who achieved complete response (CR) or partial response (PR) showed long-term responses, with a median progression free survival (PFS) of 13.1 months. Longer follow-up time of the patients demonstrated an approximately 6% CR rate9. A follow-up phase III RCT by Schwartzentruber et al.10demonstrated a small but statistically significant improvement in objective response rate (ORR) associated with the addition of the gp100 peptide vaccine to high dose IL-2, although, again, in only a small percentage of patients (16% vs. 6%) treated with vaccine plus IL-2 versus IL-2 alone.

    Immune checkpoint inhibitors have also been successfully used to treat melanoma. This therapy is based on the fact that T lymphocytes are critical to antitumor immunity, and activation by an antigen-specific T cell receptor in the context of costimulatory activation is required. However, a naturally occurring feedback mechanism that prevents excess immune activation through the expression of negative costimulatory molecules exists11. These negative costimulatory molecules, also known as “checkpoints”, such as cytotoxic T-lymphocyte antigen 4 (CTL A-4), programmed death 1 (PD-1), T cell immunoglobulin 3, and lymphocyte-activation gene 3, act as“brakes” on T cell activation and serve as negative feedback mechanism11. Interestingly, tumor-infiltrating T lymphocytes (TIL) in many tumor types express high levels of negative costimulatory markers, suggesting a tumor-derived mechanism of suppressing antitumor immunity and providing rationale for T cell checkpoint blockade12.

    In a milestone phase III RCT of 676 patients with unresectable stage III or IV melanoma treated with either anti-CTL A-4 antibody ipilimumab, gp100 peptide vaccine, or combined ipilimumab plus vaccine, patients treated with either ipilimumab arm had improved overall survival (OS) compared with those treated with vaccine alone (10.0 vs. 6.4 months)13. Ipilimumab alone achieved the best overall response rate in 10.9% of patients, and 60% of these patients benefitted from long-term responses lasting greater than 2 years. However, ipilimumab therapy was also associated with higher toxicity rate, with 10%-15% of patients suffering from grade 3 or 4 immune-related adverse events (AEs) such as diarrhea or colitis, dermatitis, and pruritis13. Similar results were reported in a second RCT, which compared ipilimumab plus dacarbazine versus dacarbazine alone in 502 patients with advanced melanoma, but this study utilized a higher dose (10 mg/kg) of ipilimumab14. Response rates were 15% in the ipilimumab with dacarbazine-treated group but with higher toxicities. Grade 3 or 4 AEs occurred in 56% of patients14.

    Topalian et al.15recently reported the results of the phase I trial of 296 patients with either advanced melanoma or other solid tumors, which included non-small cell lung cancer, prostate cancer, renal cell carcinoma, and colorectal cancer, in which the checkpoint blocking antibody anti-PD-1 (BMS-936558, nivolumab) achieved a 28% response rate in melanoma patients, with long-term responses longer than 1 year in 50% of responding patients. Anti-PD-1 therapy was associated with a lower rate of grade 3 or 4 AEs compared with ipilimumab. Interestingly, Topalian et al.15suggested a possible association between tumor expression of the PD-1 ligand PD-L1 and response to anti-PD-1 therapy. However, further studies are necessary to confirm this finding. In a pooled analysis of 411 melanoma patients treated with the anti-PD-1 antibody MK-3475 (pembro lizumab, M erck Sharp e & D o hme) with over 6 months of follow-up data, the ORR was 40% in ipilimumab na?ve patients and 28% in ipilimumab refractory patients16. Median PFS was 24 weeks, but median OS had not been reached at the time of analysis. Pembrolizumab was well-tolerated with 12% of patients experiencing a grade 3 or 4 AE aributed to the drug, but only 4% of patients discontinued treatment because of AE16.is agent was FDA-approved for metastatic melanoma in early September 2014.e antibody blockade of PD-L1 in the phase I trial of 207 patients using BMS-936559, including 55 with advanced melanoma, achieved an objective response in 17% of melanoma patients, with more than half of patients achieving long-term responses lasting longer than 1 year and a comparable rate of grade 3 or 4 AEs17. Although this agent is currently not being tested, two anti-PD-L1 antibodies, namely, MPDL3280A (Genentech) and MEDI4736 (MedImmune), are being tested in solid tumors under early phase clinical trials.

    In addition to their use for monotherapy, different immune checkpoint inhibitors are now being combined in clinical trials, which showed impressive response rates. In the phase I trial of 86 patients with unresectable stage III or IV melanoma treated with either concurrent or sequential ipilimumab and nivolumab, concurrent CTLA-4 and PD-1 blockade achieved a higher ORR of 40%, with 53% of patients achieving CR orPR at the maximum doses tested, whereas 31% of responders demonstrated tumor regression of 80% or more even with bulky disease18. In 53% of patients, grade 3 or 4 AEs occurred at a higher frequency in combined therapy than in monotherapy, the majority of which were reversible with appropriate supportive management18. In a recent update, the 1-year OS rate for patients treated with combined immune checkpoint inhibitors was 85%, and their 2-year survival rate was 79%19.

    Additional strategies targeting checkpoint inhibitors and other immunomodulatory molecules are currently being studied. However, a thorough discussion of these strategies (as well as other strategies such as treatment with tumor-in fi ltrating lymphocytes) is beyond the scope of this review.

    Targeted therapy

    Concurrent advances in targeted molecular therapy have also improved the treatment and prognosis of a subset of advanced melanoma patients. Approximately 50% of cutaneous melanomas harbor an activating mutation in the BRAF oncogene, leading to constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway involved in cellular proliferation and survival20. Preclinical studies of vemurafenib (PLX4032), a potent oral small molecule inhibitor of mutated BR AF, have culminated in a phase III RCT of vemurafenib versus dacarbazine in 675 patients with BRAF-mutated metastatic melanoma21. The vemurafenib arm resulted in improved OS (84% vs. 64% at 6 months) and higher response rate (48% vs. 5%) than standard chemotherapy, representing the only treatment other than anti-CTLA-4 to improve survival in metastatic melanoma21. Similar results were demonstrated in a phase III RCT, in which another potent BFV600Einhibitor, dabrafenib, was compared with dacarbazine22. Despite improvements in response rate and survival, BRAF inhibition achieved only a median PFS of 6 months, implying rapid development of tumor resistance21,22. Further investigation of resistance mechanisms has suggested that BRAF-mutated melanoma cells can maintain MAPK signaling throughF-independent activation of MEK, a kinase downstream ofF in the MAPK cascade23. Translating these fi ndings to clinical studies, Flaherty et al.24demonstrated that combined BRAF and MEK inhibition (dabrafenib plus trametinib vs. dabrafenib alone)achieved a higher overall response rate of 76% versus 54%, as well as a longer median PFS of 9.4 vs. 5.8 months. Similar to immunotherapy, combination molecular therapy, which targets multiple levels of an oncogenic signaling cascade or multiple different cell survival pathways, will likely enhance tumor response. In fact, dual immune and molecular therapy together may o ff er the best possibility of both long-term and frequent response25.

    Rationale for combination therapy

    Newly approved targeted and immune-modulating agents have provided numerous treatment options. However, the optimal sequencing of these agents remains controversial. Even though BRAF inhibition through selective BRAF inhibitors produces excellent early disease control for patients with V600E/K mutations, the response duration of this approach is limited to less than a year because of the development of multiple molecular mechanisms of resistance23,26-32. Checkpo int blo ckade with the CTLA4 inhibitor, ipilimumab, and anti-PD-1 antibodies produces responses in a minority of patients, but with longterm responses13,15. Thus, the combination of targeted therapy and immunotherapy may lead to early and robust antitumor responses from targeted therapy with long-term bene fi t from the in fl uence of immunotherapy.

    Preclinical data

    In vitrostudies

    To date, numerous studies have investigated combined targeted therapy and immunotherapy in melanoma. The first report suggesting that oncogenic BRAFV600Ecan lead to tumoral immune escape was published in 200633. Further in vitro studies have been performed after the development of specific BRAF inhibitors, and BF inhibition in BF mutant melanoma cell lines and fresh tumor digests has been demonstrated to result in up regulation (up to 100-fold) of melanoma differentiation antigens34. Additionally, inhibition with BR AF and MEK inhibitors increased the recognition of these melanoma antigens by antigen-specific T lymphocytes. However, MEK inhibitors adversely affect the T cell function whereas those treated with BR A F inhibito rs maintained functionality34. Further independent studies on the e ff ects of dabrafenib (BF inhibitor), trametinib (MEK inhibitor), or their combination on T lymphocytes have also shown that trametinib alone or in combination suppressed T-lymphocyte proliferation, cytokine production, and antigen-speci fi c expansion, whereas treatment with dabrafenib had no e ff ect35. Callahan et al.36suggested that BF inhibitors can modulate T cell function by potentiating T cell activation through ERK signaling in vitro and in vivo.

    In vivostudies

    Importantly, the e ff ect of BF inhibition has also been studied in patients with metastatic melanoma. Results showed a similar increase in melanoma differentiation antigens and a significant increase in intratumoral CD8+T cells, which were more clonal10-14 days aer initiation of BF inhibition37-39.ese fi ndings were also associated with down regulated IL-6, IL-8, IL-1α and vascular endothelial growth factor (VEGF)38,40,41.e increased immunomodulatory molecules, PD-1 and PD-L1, 10-14 days after BR AF inhibition initiation are also important, and this condition suggests a potential immune-based mechanism of resistance38.e up regulated PD-L1 expression may have been caused by in fi ltrating IFN-γ-secreting T cells42, although stromal components may also be involved43. Jiang et al.44also suggested PD-L1 expression as a mechanism of resistance to BRAF inhibitors because BRAF-resistant cell lines expressed high PD-L1, and the addition of MEK inhibitors has a suppressive e ff ect on PD-L1 expression.ese data indicate that addition of immunotherapy and specifically immune checkpoint blockade may enhance antitumoral response when combined with a BF inhibitor.

    Mouse models have provided important insights into cancer development, treatment, and therapeutic resistance. Several preclinical mouse models have been used to examine in detail the potential of combining immunotherapy with BF-targeted therapy, and most studies have indicated an additive or synergistic effect. In the syngeneic SM1 mouse model of BRAFV600Emelanoma, an improved antitumor activity was observed after combining BF inhibition with adoptively transferred T cells, leading to increased in vivo cytotoxic activity and intratumoral cytokine secretion by the transferred T cells. Interestingly, BF inhibition did not alter adoptively transferred T cell expansion, distribution, or intratumoral density45. Liu et al.41also studied the e ff ects of BF inhibition on adoptively transferred cells by using pmel-1 TCR transgenic mice on a C57BL/6 background and xenografts of melanoma cells transduced with gp100 and H-2Db.ey found an increase in T cell in fi ltration, which was associated with VEGF. Additionally, they showed that melanoma cell VEGF over expression abrogated T cell infiltration, and these findings were validated in patients treated with BRAF-directed therapy considering that down regulated intratumoral VEGF is correlated with a denser intratumoral T cell infiltrate after melanoma patients were treated with BRAF inhibitors41. Knight et al.46utilized several mouse models, which included SM1, SM1WT, and a transgenic mouse model of melanoma, to support the therapeutic potential of combining BF inhibitors and immunotherapy. They observed an increase in CD8:Treg ratio aer BF inhibition and that depleting CD8+T cells, not NK cells, was required for antitumor activity of BF inhibitors.ey also showed that CCR2 demonstrates an antitumoral role after BRAF inhibition and that combination of BRAF-targeted therapy and anti-CCL2 or anti-CD137 led to a significant increase in antitumoral activity in these mouse models46.

    However, a previous study has shown the absence of synergy in combined BRAF-targeted and immunotherapy48. This study conducted experiments using a conditional melanocytesp eci fi c expressed BFV600Eand P TEN gene that led to 100% penetrance, short latency, and lymph node and lung metastases.ese induced tumors were similar to human melanoma tumors from a histologic standpoint, but the immune response to BF inhibition was distinct from that observed in BRAF-inhibitortreated patients with metastatic melano ma38,39,48. In this model, treatment with anti-CTLA4 blockade and BRAF inhibition was not associated with improved survival or decreased tumor outgrowth48. These results are contrary to those observed in several other models. Thus, understanding the translational relevance of individual models and their utility in guiding the development of human clinical trials is important.

    Therefore, combined BRAF-targeted therapy with immunotherapy based on preclinical in vitro and in vivo work is advantageous. Aggregate data suggest that BRAF inhibitor treatment is associated with increased melanoma antigens, increased CD8 T cell in fi ltrate, and decreased immunosuppressive cytokines and VEGF early in the course of therapy (within 2 weeks of initiating treatment in patients)38,40,41. However, a simultaneous increase in immunomodulatory molecules was also found, which may contribute to therapy resistance. Adding BF-targeted therapy to a number of different treatment modalities could improve responses (Figure 1), and these combinations are currently being tested in murine models and clinical trials.

    Current and ongoing clinical trials of combined targeted and immunotherapy

    Translating the concepts derived from previous studies has aracted much aention for application in patient care seing. However, data on how to treat patients with combined targeted and immunotherapy approaches are insu ffi cient. A phase I study tested the combination of the BF inhibitor vemurafenib with the CTL A4 inhibitor ipilimumab.e fi rst coh ort of 6 patients received full dose vemurafenib at 960 mg orally twice daily for 1 month as a single agent prior to intravenous administrationof ipilimumab at the FDA-approved dose of 3 mg/kg. Dose limiting toxicity (DLT) of grade 3 transaminase elevations were noted in four patients within 2-5 weeks after the first dose of ipilimumab49. A second cohort of patients was then started, in which patients were started on lower dose vemurafenib (720 mg orally twice daily) with full dose ipilimumab. Hepatotoxicity was again observed with grade 3 transaminase elevations in two patients and grade 2 elevation in one patient49. Additionally, one patient in each cohort experienced grade 2 or 3 total bilirubin elevation. All hepatic AEs were asymptomatic and reversible either with temporary discontinuation of both study drugs or with administration of glucocorticoids. Additional AEs of interest included grade 2 temporal arteritis in one patient in cohort 1 and grade 3 rash in two patients in cohort 1.e study was discontinued because of hepatotoxicity issues49.

    An ongoing targeted and immunotherapy trial utilizes dabrafenib with or without trametinib combined with ipilimumab in patients with BRAF V600E/K-mutated metastatic melanoma (NCT01767454). At the time of data presentation at the American Society of Clinical Oncology (ASCO) meeting in June 2014, 12 patients had been enrolled on the doublet of ipilimumab with dabrafenib, and 7 patients were enrolled on triplet therapy50. No DLTs were found in the doublet arm of dabrafenib (150 mg) administered orally twice daily and in ipilimumab (3 mg/kg). Thus, a dose expansion of 30 additional patients is ongoing. Although hepatotoxicity was observed in the doublet arm, grade 3 or 4 toxicities were not noted, which is likely due to the lower propensity of hepatotoxicity seen with dabrafenib compared with vemurafenib50. Data are currently insu ffi cient to estimate the duration of bene fi t from doublet therapy.

    In the triplet cohort, two cases of colitis associated with colon perforation were noted in the first seven treated patients. Both patients required extensive courses of steroids, and one patient required surgery for management of the colon perforation. Toxicities were observed despite the use of low-dose dabrafenib 100 mg twice daily and trametinib 1 mg daily50. Accrual of patients in this cohort was suspended because of toxicity. Sequential administration of ipilimumab and trametinib in combination with dabrafenib is under consideration.

    Several other studies that combine targeted therapy and immunotherapy have been planned or are underway, each with varying dose levels and schedules of combination therapy administration (Table 1). These important trials will aid in understanding toxicity p ro fi le and provide preliminary e ffi cacy data of various combinations, including targeted treatment with checkpoint blockade, cytokine therapy, T cell therapy, or radiation. Many of these trials were based on the backbone of dabrafenib- and trametinib-targeted therapy with some variations on the use of BFi or MEKi alone.is condition is expected to establish whether MEKi is truly detrimental when combined with immunotherapy.

    The encouraging data regarding checkpoint blockade make these agents ideal for combination with targeted therapy. Given that the side effect profiles, response rates, and durations of response differ among CTLA4, PD-1, and PD-L1 blockers, these trials will be instrumental in providing toxicity and e ffi cacy data. Most of these trials have been designed to involve di ff erent cohorts to determine whether the combination drugs should be started simultaneously or whether targeted therapy should be administered fi rst.

    Given that cytokine therapy has long been the primary treatment for advanced stage melanoma, combined targeted treatment and cytokines are currently under clinical investigation. Combination therapy is expected to increase immune recognition o f melan oma cells by CD8 T cells thro ugh u p regulatio n of IFN-αR1 and class I HLA expression. Skin and hepatotoxicity could be overlapping for the vemurafenib and cytokine trials.us, e ffi cacy and toxicity data should be ascertained.

    Infusion of TIL for therapeutic benefit in patients is an active area of research interest and is among the most e ff ective immunotherapies in melanoma with approximately 45% ORR51. A murine adoptive cell therapy model was utilized to illustrate that selective BRAF inhibitor PLX4720 could increase tumor infiltration of adoptively transferred T cells and enhance the antitumor activity of the T cells41. This process was mediated by inhibiting the production of VEGF by melanoma cells.is finding was also verified in human melanoma patient tumor samples before and during BF inhibition41. Multiple TIL with targeted therapy trials are ongoing (Table 1).

    Selective BRAF inhibitors produce objective responses in patients with CNS disease52. However, data on the combined use of targeted therapy with radiation are insu ffi cient. Although abscopal effect has been reported with use of ipilimumab and concurrent radiation53, this phenomenon has been less well studied with targeted therapy agents. A recent publication has reported a patient with BRAF-mutated melanoma who developed progressive disease in the brain and pelvic lymph nodes after single-agent vemurafenib treatment. Vemurafenib was discontinued, and the patient was treated with stereotactic radiosurgery (SRS) to three CNS metastases, in which imaging showed complete resolution of pelvic nodes 1 month after SRS and no evidence of CNS disease for at least 18 months. The recent use of BRAF inhibitor in this patient was assumed to have facilitated a more favorable tumor microenvironment with enhanced antigen presentation to tumor cells that was augmented with the use of SRS54. Together with plannedimmune correlative studies, these ongoing studies were designed to assess whether the addition of the BRAF-targeted agent improves disease-free survival rate compared with radiation alone to help beer study the hypothesized abscopal e ff ect.

    Table 1 Phase I/II studies of combining targeted and immunotherapy in melanoma

    Future directions

    Metastatic melanoma treatment has been revolutionized over the past few years with the development of immunotherapeutic and targeted agents that improve the OS of patients. Although both immunotherapy and targeted therapies have distinct advantages and disadvantages, preclinical data suggest that combinations of these treatments could further improve patient outcomes. Data of patients who were treated with combined therapy are limited. Response data are therefore insufficient to make conclusions. However, the development of toxicities has been an issue, and controversial questions remain unclear.

    The optimal timing and sequence of combination therapy is currently unknown. Trials are being conducted to ascertain whether the agents should be administered simultaneously or targeted agents should be used fi rst to prime the T cell response. Serial biopsies in a single patient on combined vemurafenib and ipilimumab showed increased T cell infiltrate and increase in CD8:Treg ratio, which was transient but increased again after the addition of checkpoint blockade. The presence of CD8 T cell in fi ltrate on day 8 and its marked reduction on day 35 show that initiation of immunotherapy should be applied early in the course of targeted therapy to take advantage of the dense T cell infiltrate early after targeted therapy initiation. This result is limited to a single patient, but has been replicated in the subcutaneous implantable tumor model generated from a wellestablished murine model of BF mutant melanoma47.

    Whether the addition of MEK inhibition combined with immune checkpoint blockade (MEK inhibitors) suppresses T cell function in vitro remains debatable34. Studies are currently being conducted to clarify whether this condition will affect potential synergy in vivo. However, existing data suggest that the addition of MEK inhibitors to targeted and immunotherapy combinations may be associated with increased toxicity, given that in a recent study, several patients who underwent dabrafenib, trametinib, and ipilimumab treatment developed AEs related to colonic perforation50. This result, which was unexpected and found in a limited number of patients, highlights the need to further understand the immuno modulatory e ff ects of trametinib.

    In summary, metastatic melanoma treatment may have undergone much development, but this progress has resulted in the complexity of managing melanoma patients.e appropriate timing and sequence with molecularly targeted therapy and immunotherapy remains controversial, and synergy is suggested to exist between the two approaches. However, this synergy is tempered by a potential increase in toxicity. Further studies should be performed to increase the understanding of the responses to these types of therapy, and insights gained will help guide optimal management of melanoma patients.

    Acknowledgements

    Jennifer A. Wargo acknowledges NIH grants 1K08CA160692-01A1, U54CA163125-01 and the generous philanthropic support of several families whose lives have been affected by melanoma.

    Con fl ict of interest statement

    Jennifer A. Wargo has honoraria from the speakers’ bureau of DAVA Oncology and is an advisory board member for Glaxo Smith Kline, Roche/Genentech, and Amgen. No potential con fl icts of interest were disclosed by the other authors.

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.

    4. Costanza ME, Nathanson L, Costello WG, Wolter J, Brunk SF, Colsky J, et al. Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma. Cancer 1976;37:1654-1659.

    5. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011;47:1476-1483.

    6. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007;(1):CD005413.

    7. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25:5426-5434.

    8. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.

    9. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6 Suppl 1:S11-S14.

    10. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-2127.

    12. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-speci fi c CD8 T cells in fi ltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-1544.

    13. Hodi FS, O’Day SJ, McDermoDF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.

    15. Topalian SL, Hodi FS, Brahmer JR, Geinger SN, Smith DC, McDermoDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.

    16. Ribas A , Hodi FS, Ke ff ord R, Hamid O, Daud A, Wolchok JD, et al. E ffi cacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 2014;32:abstr LBA9000.

    17. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.

    18. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133.

    19. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon, Segal NH, et al. Survival, response duration, and activity by BF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014;32:abstr LBA9003.

    20. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, et al. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 2009;15:7538-7546.

    21. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BF V600E mutation. N Engl J Med 2011;364:2507-2516.

    22. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.

    23. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson L A, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-972.

    24. Flaherty KT, Infante JR, Daud A , Gonzalez R, Ke ff ord RF, Sosman J, et al. Combined BF and MEK inhibition in melanoma with BF V600 mutations. N Engl J Med 2012;367:1694-1703.

    25. Gorantla VC, Kirkwood JM. State of melanoma: an historic overview of a fi eld in transition. Hematol Oncol Clin North A m 2014;28:415-435.

    26. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al.Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.

    27. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-504.

    28. Montagut C, Sharma SV, Shioda T, McDermoU, Ulman M, Ulkus LE, et al. Elevated CF as a potential mechanism of acquired resistance to BF inhibition in melanoma. Cancer Res 2008;68:4853-4861.

    29. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-F inhibition. Proc Natl Acad Sci U S A 2009;106:20411-20416.

    31. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identi fi es (V600E)B-F ampli fi cation-mediated acquired B-F inhibitor resistance. Nat Commun 2012;3:724.

    32. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al.F inhibitor resistance is mediated by dimerization of aberrantly spliced BF(V600E). Nature 2011;480:387-390.

    33. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y.e BFMAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651-1656.

    34. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BFV600E inhibition enhances T-cell recognition of melanoma without a ff ecting lymphocyte function. Cancer Res 2010;70:5213-5219.

    35. Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL,et al. MEK inhibition, alone or in combination with BF inhibition, a ff ects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res 2014;2:351-360.

    36. Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by aF inhibitor. Cancer Immunol Res 2014;2:70-79.

    37. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, et al. BF inhibition is associated with increased clonality in tumor-in fi ltrating lymphocytes. Oncoimmunology 2013;2:e26615.

    38. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-1231.

    40. Khalili JS, Liu S, Rodríguez-Cruz TG, Whiington M, Wardell S, Liu C, et al. Oncogenic BF(V600E) promotes stromal cellmediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012;18:5329-5340.

    41. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BF inhibition increases tumor in fi ltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403.

    42. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.

    43. Frederick DT, Ahmed Z, Cooper ZA, Lizee G, Hwu P, Ferrone CR, et al. Stromal fi broblasts contribute to the up-regulation of PD-L1 in melanoma aer BF inhibition. Society For Melanoma Research 2013 International Congress; 2013; Philadelphia, PA; 2013:950-1.

    44. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS.e activation of MAPK in melanoma cells resistant to BF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.

    46. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BF inhibitors. J Clin Invest 2013;123:1371-1381.

    47. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, et al. Response to BF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014;2:643-654.

    48. Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective BF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 2012;1:609-617.

    49. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-1366.

    50. Puzanov I, Callahan MK, Linee GP, Patel SP, Luke JJ, Sosman JA, et al. Phase 1 study of the BF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). J Clin Oncol 2014;32:abstr 2511.

    51. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Speci fi c lymp ho cyte subsets predict resp onse to ad optive cell therapy using expanded autologous tumor-in fi ltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-6770.

    52. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.

    53. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal e ff ect in a patient with melanoma. N Engl J Med 2012;366:925-931.

    54. Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A. Case records of the Massachuses General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med 2013;369:173-183.

    Cite this article as:Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014;11:237-246. doi: 10.7497/j.issn.2095-3941.2014.04.002

    *These authors contributed equally to this work.

    Zachary A. Cooper and Jennifer A. Wargo

    E-mail: zcooper@mdanderson.org and jwargo@mdanderson.org Received September 9, 2014; accepted October 13, 2014.

    Available at www.cancerbiomed.org

    Copyright ? 2014 by Cancer Biology & Medicine

    少妇高潮的动态图| 国产高清有码在线观看视频| 国产黄频视频在线观看| 国产成人精品福利久久| 高清毛片免费看| 水蜜桃什么品种好| 人人妻人人添人人爽欧美一区卜| 少妇人妻久久综合中文| 在线天堂最新版资源| av在线老鸭窝| 中文乱码字字幕精品一区二区三区| 搡老乐熟女国产| 成人黄色视频免费在线看| 人体艺术视频欧美日本| 日韩电影二区| 一级黄片播放器| 观看美女的网站| 精品国产一区二区久久| 最近中文字幕2019免费版| 少妇精品久久久久久久| 国产黄色视频一区二区在线观看| 99九九线精品视频在线观看视频| 99热国产这里只有精品6| 国产黄色免费在线视频| 成年人免费黄色播放视频 | 国产一区二区在线观看av| 午夜福利在线观看免费完整高清在| 午夜影院在线不卡| 免费黄色在线免费观看| 国产精品欧美亚洲77777| 国产黄频视频在线观看| 色网站视频免费| 国产精品人妻久久久久久| 黑人巨大精品欧美一区二区蜜桃 | 男人狂女人下面高潮的视频| 亚洲高清免费不卡视频| 国产欧美日韩综合在线一区二区 | 大话2 男鬼变身卡| 亚洲性久久影院| 国产精品麻豆人妻色哟哟久久| 日韩一区二区三区影片| 美女福利国产在线| 国产男女内射视频| 69精品国产乱码久久久| 美女脱内裤让男人舔精品视频| 日本91视频免费播放| videossex国产| 日本猛色少妇xxxxx猛交久久| 亚洲精品,欧美精品| 国产在线免费精品| av黄色大香蕉| 久久人人爽人人片av| 嫩草影院入口| 搡老乐熟女国产| 日本vs欧美在线观看视频 | 国模一区二区三区四区视频| 午夜激情久久久久久久| 国产一区二区在线观看日韩| 亚洲激情五月婷婷啪啪| 欧美激情极品国产一区二区三区 | 国产真实伦视频高清在线观看| 成年美女黄网站色视频大全免费 | 久久国产精品男人的天堂亚洲 | 亚洲欧美精品自产自拍| 少妇被粗大的猛进出69影院 | 久久精品国产亚洲网站| 国产成人免费无遮挡视频| av一本久久久久| 国产成人免费观看mmmm| 99久久中文字幕三级久久日本| 国产精品偷伦视频观看了| 国产av精品麻豆| 人人妻人人看人人澡| 能在线免费看毛片的网站| 少妇人妻久久综合中文| 三级国产精品欧美在线观看| 五月开心婷婷网| a级片在线免费高清观看视频| 久久久国产欧美日韩av| 另类精品久久| 女性被躁到高潮视频| 国产国拍精品亚洲av在线观看| 中文精品一卡2卡3卡4更新| 国产黄频视频在线观看| 美女主播在线视频| 伦精品一区二区三区| 韩国av在线不卡| 亚洲精品日本国产第一区| 国产av国产精品国产| 久久久久人妻精品一区果冻| 中国三级夫妇交换| 搡女人真爽免费视频火全软件| 永久免费av网站大全| 精品熟女少妇av免费看| 久久女婷五月综合色啪小说| 精品人妻熟女毛片av久久网站| 久久毛片免费看一区二区三区| 欧美精品高潮呻吟av久久| 国产91av在线免费观看| 国产乱来视频区| 国产精品久久久久久精品电影小说| 王馨瑶露胸无遮挡在线观看| 久久久久久久精品精品| 成人漫画全彩无遮挡| 国产国拍精品亚洲av在线观看| 国产一区二区在线观看av| 国产熟女午夜一区二区三区 | 国产精品99久久久久久久久| 男女无遮挡免费网站观看| 亚洲av在线观看美女高潮| 国产精品蜜桃在线观看| 国产日韩欧美视频二区| 日韩亚洲欧美综合| 一区二区三区乱码不卡18| 午夜免费鲁丝| 精品一区在线观看国产| 亚洲自偷自拍三级| 精品一区二区免费观看| 国产一区二区三区av在线| 日韩人妻高清精品专区| 蜜桃在线观看..| 国产日韩欧美在线精品| 在线观看www视频免费| 99九九在线精品视频 | 日韩 亚洲 欧美在线| 中文乱码字字幕精品一区二区三区| 99久国产av精品国产电影| 春色校园在线视频观看| 国模一区二区三区四区视频| 免费观看无遮挡的男女| 午夜免费鲁丝| 亚洲情色 制服丝袜| 精品一区在线观看国产| a级毛片免费高清观看在线播放| 高清av免费在线| 日韩不卡一区二区三区视频在线| 久久99精品国语久久久| 亚洲精品乱码久久久久久按摩| 亚洲欧美一区二区三区黑人 | 亚洲国产日韩一区二区| 亚洲在久久综合| 亚洲,欧美,日韩| 伊人久久精品亚洲午夜| 一个人看视频在线观看www免费| 亚洲无线观看免费| 亚洲精品一二三| 国产午夜精品一二区理论片| 国产精品国产av在线观看| 亚洲精品一二三| 国产在线男女| 天天躁夜夜躁狠狠久久av| 久久国产乱子免费精品| 国产黄频视频在线观看| 中文欧美无线码| 国产熟女午夜一区二区三区 | 人体艺术视频欧美日本| av网站免费在线观看视频| av福利片在线| 久久久午夜欧美精品| 边亲边吃奶的免费视频| 免费观看av网站的网址| 色网站视频免费| 人体艺术视频欧美日本| 亚洲av二区三区四区| av有码第一页| 黄色一级大片看看| 久久久久国产网址| 看免费成人av毛片| 国产精品一区二区三区四区免费观看| 内射极品少妇av片p| 久久久欧美国产精品| 在线播放无遮挡| 熟女av电影| 人人妻人人爽人人添夜夜欢视频 | 亚洲欧美一区二区三区黑人 | 欧美精品高潮呻吟av久久| 极品少妇高潮喷水抽搐| 久久久久久久亚洲中文字幕| 精品亚洲成a人片在线观看| 涩涩av久久男人的天堂| 欧美丝袜亚洲另类| 免费看av在线观看网站| 特大巨黑吊av在线直播| 中文字幕制服av| 亚洲图色成人| 久久国产精品男人的天堂亚洲 | av免费在线看不卡| 精品午夜福利在线看| 日韩av免费高清视频| 国产高清国产精品国产三级| 国产亚洲最大av| 在线观看国产h片| 校园人妻丝袜中文字幕| 最近中文字幕高清免费大全6| 校园人妻丝袜中文字幕| 午夜福利视频精品| 婷婷色综合www| 熟女人妻精品中文字幕| 色视频www国产| 亚洲国产欧美日韩在线播放 | 日韩,欧美,国产一区二区三区| 欧美日本中文国产一区发布| 国产av精品麻豆| 天天操日日干夜夜撸| 街头女战士在线观看网站| 国产熟女午夜一区二区三区 | 国产女主播在线喷水免费视频网站| 日本免费在线观看一区| 中文天堂在线官网| 亚洲美女黄色视频免费看| 视频区图区小说| 日韩中文字幕视频在线看片| 一级毛片电影观看| 免费大片18禁| 18禁在线无遮挡免费观看视频| 色婷婷久久久亚洲欧美| 国产精品伦人一区二区| 新久久久久国产一级毛片| 青春草视频在线免费观看| 人人妻人人爽人人添夜夜欢视频 | 日韩av不卡免费在线播放| 只有这里有精品99| 丰满人妻一区二区三区视频av| 亚洲欧洲日产国产| 国产黄片视频在线免费观看| 一本久久精品| 秋霞在线观看毛片| 老熟女久久久| 80岁老熟妇乱子伦牲交| kizo精华| 色网站视频免费| 精品熟女少妇av免费看| 久久99蜜桃精品久久| 少妇人妻久久综合中文| 午夜激情久久久久久久| 国产高清国产精品国产三级| 少妇裸体淫交视频免费看高清| 最后的刺客免费高清国语| 国产老妇伦熟女老妇高清| 精品人妻熟女av久视频| 国产欧美日韩一区二区三区在线 | 免费看日本二区| tube8黄色片| 欧美+日韩+精品| 国产精品久久久久久久电影| 亚洲精品久久久久久婷婷小说| 少妇被粗大猛烈的视频| 99久久中文字幕三级久久日本| 日本猛色少妇xxxxx猛交久久| 水蜜桃什么品种好| 18禁动态无遮挡网站| 国产精品国产av在线观看| 免费看光身美女| 日本免费在线观看一区| 91午夜精品亚洲一区二区三区| 美女主播在线视频| 啦啦啦在线观看免费高清www| 欧美性感艳星| 久久国内精品自在自线图片| 国产 精品1| 99热这里只有精品一区| 久久久欧美国产精品| 国产男女超爽视频在线观看| 精品人妻偷拍中文字幕| 五月伊人婷婷丁香| 在线观看三级黄色| 人人妻人人添人人爽欧美一区卜| 亚洲国产最新在线播放| 亚洲欧美日韩另类电影网站| 国产亚洲欧美精品永久| av天堂久久9| 高清欧美精品videossex| 欧美成人精品欧美一级黄| 青春草视频在线免费观看| 一个人看视频在线观看www免费| 中文字幕人妻丝袜制服| 男女啪啪激烈高潮av片| 一区二区av电影网| 伦理电影免费视频| 国产精品久久久久成人av| 极品教师在线视频| 久久这里有精品视频免费| 大香蕉久久网| freevideosex欧美| 黑人高潮一二区| 黄色毛片三级朝国网站 | 麻豆成人av视频| 一个人看视频在线观看www免费| 国产精品久久久久久精品古装| 欧美精品一区二区大全| 国产69精品久久久久777片| 99久久精品国产国产毛片| 我要看黄色一级片免费的| av国产久精品久网站免费入址| 激情五月婷婷亚洲| 日本vs欧美在线观看视频 | 男人和女人高潮做爰伦理| 久久久久久久精品精品| 国产精品国产三级国产av玫瑰| 亚洲欧美精品专区久久| 国产av精品麻豆| 人妻一区二区av| 大又大粗又爽又黄少妇毛片口| 久久久久久久大尺度免费视频| 一本久久精品| 免费观看性生交大片5| 大码成人一级视频| 26uuu在线亚洲综合色| 一级,二级,三级黄色视频| 国产精品一区二区在线观看99| h视频一区二区三区| 亚洲精品乱码久久久v下载方式| 亚洲精品第二区| 99久久精品国产国产毛片| 亚洲欧美日韩卡通动漫| 欧美另类一区| 18禁裸乳无遮挡动漫免费视频| 深夜a级毛片| 日韩人妻高清精品专区| 成人免费观看视频高清| a级片在线免费高清观看视频| 久久久a久久爽久久v久久| 女的被弄到高潮叫床怎么办| 日本91视频免费播放| av女优亚洲男人天堂| 丰满少妇做爰视频| 久久人人爽av亚洲精品天堂| 黄片无遮挡物在线观看| 少妇高潮的动态图| 大又大粗又爽又黄少妇毛片口| a级毛色黄片| 女人精品久久久久毛片| av天堂中文字幕网| 亚洲av在线观看美女高潮| 久久久久国产精品人妻一区二区| av在线播放精品| 国产精品免费大片| 免费播放大片免费观看视频在线观看| 两个人的视频大全免费| 人妻制服诱惑在线中文字幕| 欧美97在线视频| 国产91av在线免费观看| 国产 精品1| 精品少妇内射三级| 91久久精品国产一区二区三区| 亚洲国产av新网站| 亚洲精品久久久久久婷婷小说| .国产精品久久| 久久亚洲国产成人精品v| 老女人水多毛片| 国产精品伦人一区二区| 亚洲精品日本国产第一区| 中文字幕av电影在线播放| 亚洲欧洲日产国产| 99热网站在线观看| 国产精品福利在线免费观看| 免费观看av网站的网址| 欧美激情极品国产一区二区三区 | 日韩一区二区视频免费看| 久久精品国产亚洲av天美| 建设人人有责人人尽责人人享有的| 日韩欧美精品免费久久| 色视频在线一区二区三区| 多毛熟女@视频| 久久99热6这里只有精品| 最后的刺客免费高清国语| 丰满迷人的少妇在线观看| 国产男人的电影天堂91| 精品国产一区二区久久| 男女边摸边吃奶| 大话2 男鬼变身卡| 99视频精品全部免费 在线| 内射极品少妇av片p| 两个人免费观看高清视频 | 国产黄片美女视频| 欧美成人午夜免费资源| 建设人人有责人人尽责人人享有的| 少妇猛男粗大的猛烈进出视频| 精品国产一区二区久久| 久久鲁丝午夜福利片| 国产在线男女| 日韩精品免费视频一区二区三区 | 国产av国产精品国产| 黄色怎么调成土黄色| 91精品伊人久久大香线蕉| 精品久久久精品久久久| 国产亚洲精品久久久com| 国产美女午夜福利| 建设人人有责人人尽责人人享有的| 亚洲精品中文字幕在线视频 | 亚洲不卡免费看| 国产高清三级在线| 少妇被粗大的猛进出69影院 | 少妇人妻一区二区三区视频| 久久影院123| 51国产日韩欧美| 久久精品熟女亚洲av麻豆精品| 亚洲欧美一区二区三区黑人 | 国产成人精品福利久久| av.在线天堂| 亚洲精品久久久久久婷婷小说| 少妇人妻 视频| 2018国产大陆天天弄谢| 日韩一区二区三区影片| 三上悠亚av全集在线观看 | 亚洲精品,欧美精品| 亚洲国产精品专区欧美| 一级片'在线观看视频| 少妇裸体淫交视频免费看高清| 性色avwww在线观看| 久久久久国产精品人妻一区二区| 国产日韩欧美在线精品| 日本午夜av视频| 黄色视频在线播放观看不卡| 女性生殖器流出的白浆| 精品一区在线观看国产| 十八禁高潮呻吟视频 | 亚洲欧美清纯卡通| 亚洲精品一二三| 色吧在线观看| 欧美丝袜亚洲另类| 欧美xxⅹ黑人| 国产精品久久久久久av不卡| 亚洲无线观看免费| 国产一区亚洲一区在线观看| 在线观看www视频免费| 制服丝袜香蕉在线| 久久青草综合色| 久热这里只有精品99| 久久精品国产自在天天线| 欧美精品亚洲一区二区| 国产av精品麻豆| 国产成人免费无遮挡视频| 久久久精品免费免费高清| 成人国产麻豆网| 亚洲精品中文字幕在线视频 | 日本猛色少妇xxxxx猛交久久| 亚洲人成网站在线播| 欧美亚洲 丝袜 人妻 在线| 国产精品久久久久成人av| www.av在线官网国产| 在线观看国产h片| 免费黄频网站在线观看国产| 中文欧美无线码| 成年人午夜在线观看视频| 最黄视频免费看| 欧美日韩在线观看h| 免费观看无遮挡的男女| 99热这里只有是精品50| freevideosex欧美| 国产成人a∨麻豆精品| 国产av一区二区精品久久| 久久久久久伊人网av| 国产精品伦人一区二区| 欧美最新免费一区二区三区| 色哟哟·www| 高清毛片免费看| 午夜日本视频在线| 插阴视频在线观看视频| 日本黄色日本黄色录像| 国产精品免费大片| tube8黄色片| 久久精品久久久久久噜噜老黄| 在线免费观看不下载黄p国产| 亚洲欧美一区二区三区黑人 | 王馨瑶露胸无遮挡在线观看| 国产免费又黄又爽又色| 成人毛片a级毛片在线播放| av天堂久久9| 美女中出高潮动态图| 十分钟在线观看高清视频www | 亚洲中文av在线| 一级二级三级毛片免费看| 亚洲丝袜综合中文字幕| 我的女老师完整版在线观看| 晚上一个人看的免费电影| 婷婷色麻豆天堂久久| 曰老女人黄片| 亚洲国产精品一区二区三区在线| 亚洲婷婷狠狠爱综合网| 精品少妇黑人巨大在线播放| 久久久精品94久久精品| 久久精品熟女亚洲av麻豆精品| 亚洲一级一片aⅴ在线观看| 老熟女久久久| 亚洲美女视频黄频| 国产无遮挡羞羞视频在线观看| 日韩av不卡免费在线播放| 亚洲人与动物交配视频| 亚洲精品日韩av片在线观看| 国产在线一区二区三区精| 久久人人爽人人爽人人片va| 国产精品99久久久久久久久| 六月丁香七月| 国产免费一级a男人的天堂| 天堂俺去俺来也www色官网| 少妇丰满av| tube8黄色片| 国产视频首页在线观看| 人妻制服诱惑在线中文字幕| 99久国产av精品国产电影| 亚洲精品视频女| 在线亚洲精品国产二区图片欧美 | 最后的刺客免费高清国语| 国内少妇人妻偷人精品xxx网站| 国产亚洲一区二区精品| 精品久久久久久电影网| 久久这里有精品视频免费| 免费观看性生交大片5| 欧美日韩一区二区视频在线观看视频在线| 一级黄片播放器| 免费播放大片免费观看视频在线观看| 大又大粗又爽又黄少妇毛片口| 久久ye,这里只有精品| 成年人免费黄色播放视频 | 国产一区二区三区综合在线观看 | 日本av手机在线免费观看| 久久久久久久久久人人人人人人| 狂野欧美白嫩少妇大欣赏| 看非洲黑人一级黄片| 国产精品麻豆人妻色哟哟久久| av一本久久久久| 看十八女毛片水多多多| 精品一区二区三区视频在线| 深夜a级毛片| 老女人水多毛片| 中国国产av一级| 国产男女超爽视频在线观看| 精品人妻熟女av久视频| 久久久久精品久久久久真实原创| 夜夜爽夜夜爽视频| 色视频在线一区二区三区| 日本免费在线观看一区| 国产69精品久久久久777片| 国产成人免费观看mmmm| 国产精品不卡视频一区二区| videossex国产| 国产永久视频网站| 欧美日韩亚洲高清精品| 2018国产大陆天天弄谢| 黄色配什么色好看| 日韩亚洲欧美综合| 国产精品成人在线| 亚洲国产毛片av蜜桃av| 黄色怎么调成土黄色| 日本-黄色视频高清免费观看| 日本黄色片子视频| 我的女老师完整版在线观看| 日日摸夜夜添夜夜添av毛片| 精品国产国语对白av| 亚洲激情五月婷婷啪啪| 丝瓜视频免费看黄片| 夫妻午夜视频| 久久女婷五月综合色啪小说| 亚洲精品第二区| www.色视频.com| 欧美变态另类bdsm刘玥| 国产免费一区二区三区四区乱码| 亚洲一区二区三区欧美精品| 亚洲国产精品国产精品| √禁漫天堂资源中文www| h日本视频在线播放| 熟女人妻精品中文字幕| 欧美精品国产亚洲| 亚洲第一av免费看| 观看美女的网站| 午夜福利在线观看免费完整高清在| 丰满饥渴人妻一区二区三| 99久久中文字幕三级久久日本| 久久av网站| 夜夜骑夜夜射夜夜干| 一区二区三区精品91| 欧美精品高潮呻吟av久久| 亚洲情色 制服丝袜| 天堂中文最新版在线下载| 国产精品久久久久久精品古装| 777米奇影视久久| 岛国毛片在线播放| 欧美xxxx性猛交bbbb| 色婷婷av一区二区三区视频| 国产成人午夜福利电影在线观看| 精品久久久精品久久久| 亚洲美女黄色视频免费看| 午夜影院在线不卡| 黄色怎么调成土黄色| 交换朋友夫妻互换小说| 久久精品国产a三级三级三级| 成人影院久久| 插逼视频在线观看| 色视频www国产| 亚州av有码| 免费大片黄手机在线观看| 亚洲人与动物交配视频| 七月丁香在线播放| 亚洲在久久综合| 在现免费观看毛片| 欧美日韩在线观看h| 男女无遮挡免费网站观看| 久久青草综合色| 天天躁夜夜躁狠狠久久av| 久久精品国产亚洲av天美| 一级二级三级毛片免费看| 在线看a的网站| 九九爱精品视频在线观看| 久久影院123| 大话2 男鬼变身卡| 高清毛片免费看| 9色porny在线观看| 亚洲精品aⅴ在线观看| 亚洲精品一区蜜桃| 9色porny在线观看| 天天操日日干夜夜撸| 日日啪夜夜爽| 精品少妇久久久久久888优播| 男的添女的下面高潮视频|